C Hu, FS Wong, L Wen - Clin Exp Immunol, 2009 - interscience.wiley.com B cells play an important role in the pathogenesis of both systemic and
organ-specific autoimmune diseases. Autoreactive B cells not only produce
autoantibodies, but are also specialized to efficiently present specific ... Cited by 2 - Related articles - All 3 versions
SK O'Neill, E Liu, JC Cambier - Current Opinion in Endocrinology, Diabetes and …, 2009 - journals.lww.com Introduction The failure to find a cure for type 1 diabetes has led to the
exploration of efficacious immunotherapies already approved for other diseases.
A recent TrialNet study exploring the use of rituximab in new onset type 1 ... Related articles - All 2 versions
SL Cox, PA Silveira - Expert Review of Clinical Immunology, 2009 - ingentaconnect.com Type 1 diabetes (T1D) is caused by immune infiltration of the pancreatic islets
of Langerhans (referred to as insulitis) followed by specific auto-
immune-mediated destruction of the insulin- secreting b-cells within them ... Related articles - All 3 versions
PL Kendall, DJ Moore, C Hulbert, KL Hoek, … - The Journal of Immunology, 2009 - Am Assoc Immnol Type 1 diabetes results from T cell-mediated destruction of insulin-producing ß
cells. Although elimination of B lymphocytes has proven successful at preventing
disease, modulation of B cell function as a means to prevent type 1 ... Related articles - All 3 versions
C Hu, FS Wong, L Wen - Clinical and Experimental Immunology, 2009 - pt.wkhealth.com B cells play an important role in the pathogenesis of both systemic and
organ-specific autoimmune diseases. Autoreactive B cells not only produce
autoantibodies, but are also specialized to present specific autoantigens ...
HHM Abdu-Allah, K Watanabe, K Hayashizaki, … - Tetrahedron Letters, 2009 - Elsevier Synthetic ligands tagged with biotin have frequently been utilized to detect,
localize, characterize and recover the target protein. 4 Moreover, in order to
pursue CD22 as a drug target, precise and reproducible binding assays need ... Related articles
- ►rexnealsmith.com [PDF] P Fiorina, M Jurewicz, A Augello, A Vergani, … - The Journal of Immunology, 2009 - Am Assoc Immnol Human clinical trials in type 1 diabetes (T1D) patients using mesenchymal stem
cells (MSC) are presently underway without prior validation in a mouse model for
the disease. In response to this void, we characterized bone marrow-derived ... Related articles - All 5 versions